The role of pegvisomant in the treatment of acromegaly

Expert Opinion on Biological Therapy

Volumn 8, Issue 5, 2008, Pages 691-704

  Roelfsema, Ferdinand ^a   Biermasz, Nienke R ^a   Pereira, Alberto M ^a   Romijn, Johannes A ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Acromegaly; Growth hormone receptor; Growth hormone receptor antagonist; Medical treatment; Pegvisomant; Somatostatin analogue

Indexed keywords

ALKALINE PHOSPHATASE; AMINOTRANSFERASE; ANGIOPEPTIN; ANTISENSE OLIGONUCLEOTIDE; ATL 227446; BILIRUBIN; BROMOCRIPTINE; CABERGOLINE; GROWTH HORMONE; LIVER ENZYME; OCTREOTIDE; PEGVISOMANT; QUINAGOLIDE; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ADENOMA; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GROWTH HORMONE BLOOD LEVEL; HEART HYPERTROPHY; HUMAN; HYPOPITUITARISM; INCIDENCE; INJECTION SITE IRRITATION; LIVER FUNCTION TEST; LIVER INJURY; LOADING DRUG DOSE; REMISSION; REVIEW; SIDE EFFECT; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ACROMEGALY; CLINICAL TRIALS AS TOPIC; HUMAN GROWTH HORMONE; HUMANS; RECEPTORS, SOMATOTROPIN;

EID: 43649103813     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.8.5.691     Document Type: Review

References (99)

1. Le Roith D, Bondy C, Yakar S, et al. The somatomedin hypothesis. Endocr Rev 2001;22:53-74
2. Sjogren K, Liu JL, Blad K, et al. Liver-derived insulin-like growth factor I (IGF-I) is the principle source of IGF-I in blood but it is not required for postnatal body growth in mice. Proc Natl Acad Sci USA 1999;96:7088-92
3. Woods KA, Camacho-Hubner C, Savage MO, et al. Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene. N Engl J Med 1996;335:1363-7
4. Walenkamp MJE, Karperienm, Pereira AM, et al. Homozygous and heterozygous expression of a novel insulin-like growth factor-I mutation. J Clin Endocrinol Metab 2005;90:2855-64
5. Janssen YJH, Frolich M, Roelfsema F. A low starting dose of recombinant human growth hormone (GH) in adults with GH deficiency. J Clin Endocrinol Metab 1997;82:129-35
6. Ezzat S, Forster MJ, Berchtold P, et al. Acromegaly. Clinical and biochemical features in 500 patients. Medicine (Baltimore) 1994;73:233-40
7. Baumann G. Growth hormone heterogeneity: genes, isohormones, variants, and binding proteins. Endocr Rev 1991;12:424-49
8. Sotiropoulos A, Coujon L, Simonin G, et al. Evidence for generation of the growth hormone-binding protein through proteolysis of the growth hormone membrane receptor. Endocrinology 1993;132:1863-5
9. Giustinaa, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev 1998;19:717-97
10. Pijl H, Langendonk JG, Burggraaf J, et al. Altered neuroregulation of GH secretion in viscerally obese premenopausal women. J Clin Endocrinol Metab 2001;86:5509-15
11. Alexander L, Appleton D, Hall R, et al. Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol (Oxford) 1980;12:71-9
12. Bengtsson BA, Eden S, Ernest I, et al. Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984. Acta Med Scand 1988;223:327-35
13. Ritchie CM, Atkinson AB, Kennedy AL, et al. Ascertainment and natural history of treated acromegaly in Northern Ireland. Ulster Med J 1990;59:55-62
14. Mestron A, Webb SM, Astorga R, et al. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). Eur J Endocrinol 2004;151:439-46
15. Colao A, Ferone D, Marzullo P, et al. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 2004;25:102-52
16. Wright AD, Hill DM, Lowy C, et al. Mortality in acromegaly. Q J Med 1970;39:1-16
17. Ho KY, Weisberger AJ. Characterization of 24-hour growth hormone secretion in acromegaly: implications for diagnosis and therapy. Clin Endocrinol (Oxford) 1994;41:75-83
18. Van Den Berg G, Frolich M, Veldhuis JD, et al. Growth hormone secretion in recently operated acromegalic patients. J Clin Endocrinol Metab 1994;79:1706-15
19. Van Der Lely AJ, De Herder WW, Janssen JA, et al. Acromegaly: the significance of serum total and free IGF-I and IGF- binding protein-3 in diagnosis. J Endocrinol 1997;155(Suppl 1):S9-13; discussion S15-6:S9-13
20. Hoffman DM, O'Sullivan AJ, Baxter RC, et al. Diagnosis of growth hormone deficiency in adults. Lancet 1994;343:1064-8
21. Swaeringen B, Barker FG, Katznelson L, et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998;83:3419-26
22. Biermasz NR, Dekker FW, Pereira AM, et al. Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor-I measurements. J Clin Endocrinol Metab 2004;89:2789-96
23. Van Den Berg G, Pincus SM, Frolich M, et al. Reduced disorderliness of growth hormone release in biochemically inactive acromegaly after pituitary surgery. Eur J Endocrinol 1998;138:164-9
24. Freda PU, Wardlaw SL, Post KD. Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly. J Neurosurg 1998;89:353-8
25. Biermasz NR, Van Dulken H, Roelfsema F. Ten-year follow-up results of transsphenoidal microsurgery in acromegaly. J Clin Endocrinol Metab 2000;85:4596-602
26. Wass JA. Radiotherapy in acromegaly: a protagonist's viewpoint. Clin Endocrinol (Oxford) 2003;58:128-31
27. Biermasz NR, Van Dulken H, Roelfsema F. Postoperative radiotherapy in acromegaly is effective in reducing GH concentration to safe levels. Clin Endocrinol (Oxford) 2000;53:321-7
28. Biermasz NR, Pereira AM, Neelis KJ, et al. The role of radiotherapy in the management of acromegaly. Expert Rev Endocrinol Metab 2006;1:449-60
29. Roelfsema F, Goslings BM, Frolich M, et al. The influence of bromocriptin on serum levels of growth hormone and other pituitary hormones and its metabolic effects in active acromegaly. Clin Endocrinol (Oxford) 1979;11:235-44
30. Jaffe CA, Barkan AL. Treatment of acromegaly with dopamine agonists. Endocrinol Metab Clin North Am 1992;21:713-35
31. Abs R, Verhelst J, Maiter D, et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab 1998;83:374-8
32. Freda PU. Current concepts in the biochemical assessment of the patient with acromegaly. Growth Horm IGF Res 2003;13:171-84
33. Cozzi R, Attanasio R, Lodrini S, et al. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clin Endocrinol (Oxford) 2004;61:209-15
34. Schade R, Andersohn F, Suissa S, et al. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007;356:29-38
35. Hofland LJ, Lamberts SWJ. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 2003;24:28-47
36. Serri O, Brazeau P, Kachra Z, et al. Octreotide inhibits insulin-like growth factor-I hepatic gene expression in hypophysectomized rat: evidence for a direct and indirect mechanism of action. Endocrinology 1992;130:1816-21
37. Murray RD, Kim K, Ren S-G. Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis. J Clin Invest 2004;114:349-56
38. Lancranjan I, Atkinson AB; Sandostatin LAR Group. Results of a European multicentre study with Sandostatin LAR in acromegalic patients. Pituitary 1999;1:105-14
39. Cozzi R, Attanasio R, Montini M, et al. Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? J Clin Endocrinol Metab 2003;88:3090-8
40. Cozzi R, Montini M, Attanasio R, et al. Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab 2006;91:1397-403
41. Roelfsema F, Biermasz NR, Romijn JA, Pereira AM. Treatment strategies for acromegaly. Expert Opin Emerging Drugs 2005;10:875-90
42. Melmed S, Sternberg R, Cook D, et al. A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab 2005;90:4405-10
43. Biermasz NR, Pereira AM, Smit JW, et al. Intravenous octreotide test predicts the long term outcome of treatment with octreotide-long-acting repeatable in active acromegaly. Growth Horm IGF Res 2005;15:200-6
44. Karavitaki N, Botusan I, Radian S, et al. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly. Clin Endocrinol (Oxford) 2005;62:282-8
45. Gilbert JA, Miell JP, Chambers SM, et al. The nadir growth hormone after an octreotide test dose predicts the long-term efficacy of somatostatin analogue therapy in acromegaly. Clin Endocrinol (Oxford)62:742-7
46. Tachas G, Lofthouse S, Wraight, et al. A GH receptor antisense oligonucleotide inhibits hepatic GH receptor expression, IGF-I production and body weight gain in normal mice. J Endocrinol 2006;189:147-54
47. Ultsch M, De Vos AM, Kossiakoff AA. Crystals of the complex between human growth hormone and the extracellular domain of its receptor. J Mol Biol 1991;222:865-8
48. Ultsch M, De Vos AM. Crystals of growth hormone-receptor complexes. Extracellular domains of the growth hormone and prolactin receptors and a hormone mutant designed to prevent receptor dimerization. J Mol Biol 1993;231:1133-6
49. De Vos AM, Ultsch M, Kossiakoff AA. Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science 1992;255:306-12
50. Ultsch MH, Somers W Kossiakoff AA, et al. The crystal structure of affinity-matured growth hormone at 2 Å resolution. J Mol Biol 1994;236:286-99
51. Bazan JF. Structural design and molecular evolution of a cytokine receptor superfamily. Proc Natl Acad Sci USA 1990;87:63934-9938
52. Brown RJ, Adams JJ, Pelekanos RA, et al. Model for growth hormone receptor activation based on subunit rotation within a receptor dimer. Nat Struct Mol Biol 2005;12:814-21
53. Carter-Su C, Smit LS. Signaling via JAK tyrosine kinases: growth hormone receptor as a model system. Recent Prog Horm Res 1998;53:61-82
54. Pelekanos RA, Waters MJ. Activation of the growth hormone receptor. Expert Rev Endocrinol Metab 2006;1:189-98
55. Alves Dos Santos CM, Ten Broeke T, Strous GJ. Growth hormone receptor ubiquitination, endocytosis, and degradation are independent of signal transduction via Janus kinase 2. J Biol Chem 2001;276:32635-41
56. Van Kerkhof P, Smeets M, Strous GJ. The ubiquitin-proteasome pathway regulates the availability of the GH receptor. Endocrinology 2002;143:1243-52
57. Strous GJ, Alves Dos Santos C, Gent J, et al. Ubiquitin system-dependent regulation of growth hormone receptor signal transduction. Curr Top Microbiol Immunol 2004;286:81-118
58. Chen WY, Chen NY, Yun J, et al. In vitro and in vivo studies of antagonistic effects of human growth hormone analogs. J Biol Chem 1994;269:15892-7
59. Harding PA, Wang X, Okada S, et al. Growth hormone (GH) and a GH antagonist promote GH receptor dimerization and internalization. J Biol Chem 1996;271:6708-12
60. Rose DR, Clemmons DR. Growth hormone receptor antagonist improves insulin resistance in acromegaly. Growth Horm IGF Res 2002;12:418-24
61. Maamra M, Finidori J, Von Laue S, et al. Studies with a growth hormone antagonist and dual-fluorescent confocal microscopy demonstrate that the full-length human growth hormone receptor, but not the truncated isoform, is very rapidly internalized independent of Jak2-Stat5 signaling. J Biol Chem 1999;274:14791-8
62. Goffin V, Bernichtein S, Carriere O, et al. The growth hormone antagonist B2036 does not interact with the prolactin receptor. Endocrinology 1999;140:3853-6
63. Lowman HB, Wells JA. Affinity maturation of human growth hormone by monovalent phage display. J Mol Biol 1993;234:564-78
64. Davis FF, Abuchowski A, Van Es T, et al. Enzyme-polyethylene glycol adducts: modified enzymes with unique properties. Enzyme Eng 1978;4:169-73
65. Harris JM, Martin NE, Modi M. Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet 2001;40:539-51
66. Pradhananga S, Wilkinson I, Ross RJM. Pegvisomant: structure and function. J Mol Endocrinol 2002;29:11-4
67. Rodvold KA, Bennett WF, Zib KA. Single-dose safety and pharmacokinetics of B2036-PEG (Somavert) after subcutaneous administration in healthy volunteers [abstract]. J Clin Pharmacol 1997;37:869
68. Rodvold KA, Van Der Lely AJ. Pharmacokinetics and pharmacodynamics of B2036-PEG, a novel growth hormone receptor antagonist, in acromegalic subjects [abstract P1-049]. Proceedings 81th Annual Meeting of the Endocrine Society; 1999
69. Thorner MO, Strasburger CJ, Wu Z, et al. Growth hormone (GH) receptor blockade with a PEG-modified GH (B2036-PEG) lowers serum insulin-like growth factor-I but does not acutely stimulate serum GH. J Clin Endocrinol Metab 1999;84:2098-103
70. Veldhuis JD, Bidlingmaier M, Anderson SM, et al. Lowering total plasma insulin-like growth factor I concentrations by way of a novel, potent, and selective growth hormone (GH) receptor antagonist, pegvisomant (B2036-Peg), augments the amplitude of GH secretory bursts and elevates basal/nonpulsatile GH release in healthy women and men. J Clin Endocrinol Metab 2001;86:3304-10
71. Paisley AN, Hayden K, Ellis A, et al. Pegvisomant interference in GH assays results in underestimation of GH levels. Eur J Endocrinol 2007;156:315-9
72. Yin D, Vreeland F, Schaaaf LJ, et al. Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: implications for cancer therapy. Clin Cancer Res 2007;13:1000-9
73. Nass R, Toogood AA, Hellmann P, et al. Intracerebroventricular administration of the rat growth hormone (GH) receptor antagonist G118R stimulates GH secretion: evidence for the existence of short loop negative feedback of GH. J Neuroendocrinol 2000;12:1194-9
74. Brian SR, Bidlingmaier M, Wajnrajch MP, et al. Treatment of acromegaly with pegvisomant during pregnancy: maternal and fetal effects. J Clin Endocrinol Metab 2007;92:3374-7
75. Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 2000;342:1171-7
76. Van Der Lely AJ, Hutson RK, Trainer PJ, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001;358:1754-9
77. Schreiber I, Buchfelder M, Droste M, et al. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol 2007;156:75-82
78. Jehle S, Reyes CM, Sundeen RE, et al. Alternate-day administration of pegvisomant maintains normal serum insulin-like growth factor-1 levels in patients with acromegaly. J Clin Endocrinol Metab 2005;90:1588-93
79. Jørgensen JOL, Feldt-Rasmusen U, Frystyk J, et al. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J Clin Endocrinol Metab 2005;90:5627-31
80. Neggers JCM, Van Aken MO, Janssen JAM, et al. Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. J Clin Endocrinol Metab 2007;92:4598-601
81. NCT 00383708. Available from: www.ClinicalTrials.gov
82. NCT 0068029. Available from: www.ClinicalTrials.gov
83. Harris PE, D'Souza G, Good AJ, et al. Treatment with pegvisomant alone compared to combination therapy with pegvisomant/octreotide LAR in acromegaly [abstract OR 53-3]. The Endocrine Society Annual Meeting; 2007 June 2-5; Toronto, Ontario, Canada
84. Feenstra J, De Herder WW, Ten Have Smth, et al. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 2005;365:1644-46
85. Trainer PJ, Drake WM, Perry LA, et al. Modulation of cortisol metabolism by the growth hormone receptor antagonist pegvisomant in patients with acromegaly. J Clin Endocrinol Metab 2001;86:2989-92
86. Sesmilo G, Fairfield WP, Katznelson L, et al. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant. J Clin Endocrinol Metab 2002;87:1692-999
87. Paisley AN, O'Callaghan CJ, Lewandowski KC, et al. Reductions of circulating matrix metalloproteinase 2 and vascular endothelial growth factor levels after treatment with pegvisomant in subjects with acromegaly. J Clin Endocrinol Metab 2006;91:4635-40
88. Pivonello R, Galderisi M, Auriemma RS, et al. Treatment with growth hormone receptor antagonist in acromegaly: effect on cardiac structure and performance. J Clin Endocrinol Metab 2007;92:476-82
89. Rose DR, Clemmons DR. Growth hormone receptor antagonist improves insulin resistance in acromegaly. Growth Horm IGF Res 2002;12:418-24
90. Parkinson C, Drake WM, Roberts ME, et al. A comparison of the effects of pegvisomant and octreotide on glucose, insulin, gastrin, cholecystokinin, and pancreatic polypeptide responses to oral glucose and a standard mixed meal. J Clin Endocrinol Metab 2002;87:1797-804
91. Drake WM, Rowles SV, Roberts ME, et al. Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant. Eur J Endocrinol 2003;149:521-7
92. Barkan AL, Burman P, Clemmons DR, et al. Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. J Clin Endocrinol Metab 2005;90:5684-91
93. Lindberg-Larsen R, Moller N, Schmitz O, et al. The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly. J Clin Endocrinol Metab 2007;92:1724-8
94. Fairfield WP, Sesmilo G, Katznelson L, et al. Effects of a growth hormone receptor antagonist on bone markers in acromegaly. Clin Endocrinol (Oxford) 2002;57:385-90
95. Parkinson C, Kassem M, Heickendorff L, et al. Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal. J Clin Endocrinol Metab 2003;88:5650-5
96. Parkinson C, Burma P, Messig M, Trainer PJ. Gender, body weight, disease activity, and previous radiotherapy influence the response to pegvisomant. J Clin Endocrinol Metab 2007;92:190-5
97. Frohman LA, Bonert V. Pituitary tumor enlargement in two patients with acromegaly during pegvisomant therapy. Pituitary 2007;10:283-9
98. Biering H, Saller B, Bauditz J, et al. Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis. Eur J Endocrinol 2006;154:213-20
99. Harris P, D'Souza, Good A, et al. A comparison between the efficacy and safety of pegvisomant to that of octreotide LAR in patients with acromegaly [Endocrine Abstracts 14 P610]. Presented at European Society of Endocrinology; Budapest; 2007